Microfluidic particle analysis method, device and system

Information

  • Patent Grant
  • 10900886
  • Patent Number
    10,900,886
  • Date Filed
    Friday, April 20, 2018
    6 years ago
  • Date Issued
    Tuesday, January 26, 2021
    3 years ago
Abstract
The method, device, and system relate to particle analysis, and in particular, to a microfluidic device designed for trapping particles for analysis. Particles include beads and cells.
Description
FIELD

The device and method relate to microfluidic particle analysis. The device is designed for trapping particles for solution analysis. Exemplary particles include beads and cells.


BACKGROUND

Particle-based science and technology is an important aspect of biomedical and clinical research. Inorganic particles such as quantum dots and beads have found applications in bio-imaging and point-of-care diagnosis. These particles can further be conjugated with other materials such as proteins or DNAs for biosensors and bioassays. Living particles such as cells, viruses and bacteria are commonplace in everyday biological experiments. Through analysis of their molecular and cellular properties using techniques such as DNA sequencing, protein mapping and high content screening, these particles have greatly advanced the development of the biological sciences.


The most common particle analysis apparatus is the flow cytometer, where particles with fluorescent tags are hydrodynamically focused into a stream and excited by laser beams. The emitted fluorescence from the tags are collected by photodetectors and analyzed to extrapolate information about the biological properties of each individual particle. There are three major drawbacks of the system: 1) the system is expensive and bulky. 2) the particles can not be analyzed over time due to the single pass nature of the flow cytometer. 3) it does not resolve subcellular localization of fluorescent signals.


In order to conduct detailed analysis of the particles, it is desired to trap these particles in specific locations so they don't displace due to the forces of fluid flow, shear stress or thermal agitation during the course of the experiment. Microfluidic devices are ideal candidates for particle analysis because of their compact size, low reagent consumption and laminar flow nature. One common method of trapping particles is to use dielectrophoresis, where electrodes and electric fields are used to generate dielectrophoretic forces on particles; however, the particles trapped using this method can still rotate, and are subject to displacement when flows are introduced. In addition, the fabrication of electrodes into the device significantly increases the cost. Using a sieve at a size smaller than the particles can serve as a particle trap; however, the particles will be packed into clumps, making it difficult to analyze.


The potential advantages of a trapped particle array device have been realized to a limited extent in the prior art. Various limitations associated with prior art devices include (i) difficulty in preventing microfluidic structures from being blocked by particles within the structures, (ii) inability to trap the particles so they won't be displaced by fluidic flows, (iii) inability to provide different solutions to the particles at different times for rapid assay.


It would therefore be desirable to provide a microfluidic particle trapping device capable of more fully realizing the advantages noted above in a high throughput particle analysis system.


SUMMARY

In one aspect, a microfluidic particle analysis device is provided comprising


a microfluidics body,


formed in said body, a microfluidics channel for receiving particles at an upstream region thereof,


the channel having a deformable wall portion that defines a particle-capture region, and which is responsive to a change in fluid pressure applied thereto, to selectively vary the particle-flow dimensions of said capture region,


wherein particles having a given size may be selectively retained in said capture region.


In one embodiment, the deformable wall portion is expandable in response to a positive fluid pressure applied within the channel. In another embodiment, said deformable wall portion is expandable in response to a negative pressure applied to a cavity communicating with said wall portion, external to said channel. In some embodiments, said wall portion is deformable from a relaxed condition, at which particles of a selected size are prevented from entering the particle capture region, to a first expanded position at which particles of a selected size may enter and flow through the capture region.


In a particular embodiment, said capture region is defined by a cavity in said deformable wall portion, movement of the wall portion from its relaxed to its first expanded condition allows particles of a selected size to enter and flow through said cavity, and movement of said wall portion from its first expanded condition to its relaxed condition allows such particles to be trapped within said cavity in said capture region.


In another particular embodiment said wall portion is deformable from a relaxed condition, at which particles of a selected size are prevented from entering the particle capture region, to a first expanded position at which particles of a selected size may enter the capture region, and from the first expanded condition to a second expanded position in which the particles become trapped within said capture region.


Some embodiments comprise a microfluidic mesh in fluid contact with the microfluidic passageway, wherein the mesh prevents the passage of particles from the microfluidic passageway to a channel outlet downstream of the particle capture region. Some embodiments include an array of such channels and associated wall portions. In some embodiments, the microfluidic passageway has a plurality of longitudinally spaced capture regions, each defined by a deformable wall portion, and designed for trapping particles of different diameters.


The deformable wall portion is formed of a deformable polymer selected from the group consisting of polydimethylsiloxane (PDMS), polyisoprene, polybutadiene, polychloroprene, polyisobutylene, poly(styrene-butadiene-styrene), polyurethane, and silicone.


In some embodiments, the selectively retained (trapped) particles are addressed with a solution. In other embodiments, the selectively retained particles are addressed with a plurality of solutions in series. In particular embodiments, the solution comprises a drug, a reagent, a nutrient, blood, or serum.


In some embodiments, the solution displaces the selectively retained particles by no more than 10% of the size of the particles. In some embodiments, the solution provides fluid exchange in less than 10 seconds.


In another aspect, methods are provided for trapping particles using a microfluidic channel having a deformable wall portion.


These and other objects and features of the invention will become more fully understood when the following detailed description of the invention is read in conjunction with the accompanying drawings.





BRIEF DESCRIPTION OF THE FIGURES


FIGS. 1A-C show a top (FIG. 1A) and side (FIGS. 1B and 1C) views of a microfluidic particle trapping device with a cross-section defined by the line A-A′. FIG. 1D shows a plan view of an embodiment of the microfluidic particle trapping device with three reservoirs and a cross-section defined by the line A-A′



FIGS. 2A-2C show cross-sectional views (A-A′ in FIGS. 1A-1D) of an embodiment of the microfluidic particle trapping device in different stages of operation, and having a microfluidic channel of height H′, and trapping region internal dimension of height h′. (FIG. 2A) The deformable wall portion is in the relaxed condition, wherein the particle flow dimension (i.e., internal dimension h) is less than the diameter of the particles. (FIG. 2B) The deformable wall portion is in the expanded condition, wherein the particle flow dimension is greater than the particle diameter, allowing the particles to enter the microfluidic channel. (FIG. 2C) The deformable wall portion in the relaxed condition to trap the particles in the microfluidic channel.



FIGS. 3A and 3B show an embodiment of the device with an additional particle outlet port, multiple trapping regions with different heights, and a sieve to prevent particles from entering the solution ports. (FIG. 3A) Plan view. (FIG. 3B) Cross-section A-A′.



FIGS. 4A and 4B show cross-sectional views of an embodiment of the device in different stages of operation, and having a deformable wall with a cavity. (FIG. 4A) The device is at the first pneumatic pressure to show that the internal dimension (h′) is greater than the diameter of the particles. (FIG. 4B) The device is at the second pneumatic to trap the particles in the cavity of the deformable the deformable wall portion.



FIGS. 5A and 5B show cross-sectional views of an embodiment of the device for us with a vacuum source. (FIG. 5A) When vacuum is applied, the internal dimension (h′) is greater than the diameter of the particles. (FIG. 5B) When vacuum is released, the particles are trapped by the deformable wall portion.



FIG. 6 is a graph showing the relationship between internal dimension of the microfluidic channel (channel height h′) as a function of pneumatic pressure (P).



FIG. 7 shows a drawing of an embodiment of the device for analyzing 16 different particles with 4 different solution-switching functions.



FIG. 8 shows the particle trapping region in an embodiment of the device.



FIG. 9 shows an embodiment of the device for yeast cell imaging.



FIG. 10A shows an embodiment of the device for yeast cell imaging. FIG. 10B shows a picture of yeast cells trapped inside the channels the device shown in FIG. 10A.



FIG. 11 shows a schematic of an embodiment of the device for trapping beads as used for immunoassays.



FIG. 12 shows a cross-section of an embodiment of the device. The antibody-coated beads are concentrated inside the trapping region, and are subjected to a conventional assay protocol through reagent switching.



FIGS. 13A-13K illustrate steps in an exemplary fabrication method for making a microfluidic particle analysis device.



FIGS. 14A-14C show a control box and a manifold for use with the microfluidic particle analysis device.





DETAILED DESCRIPTION
A. Definitions

Prior to describing the present device and methods, the following terms and phrases are defined:


A “particle” refers to living or dead cells, such as mammalian, yeast, insect, and bacterial cells; beads such as polymer beads and metal beads; or other physical entities that may be trapped for analysis in accordance with the methods and device described, herein. Such particles have an average minimum diameter of between about 100 nm to about 50 μm, preferably between about 1 μm to about 30 μm, more preferably between about 2 μm to about 20 μm, and even between about 3 μm to about 10 μm. Some particles can be coated or functionalized with additional layers of materials, e.g, gold-coated or antibody-coated polystyrene beads.


The “size” of a particle generally refers to its average or typical diameter. The device and methods are for use with substantially spherical particles or particles having a less than a 2-fold and even less than a 1.5-fold difference in the major and minor elliptical axis of non-spherical particles. The particles size generally excludes such extracellular structures as flagella, cilia, pilli, pseudopods, processes, or other readily deformable structures.


A “microchannel” or “microfluidic channel” refers to a micron-scale conduit for carrying fluid, solvents, solutes, and suspended micron-scale particles. A microchannel typically has a rectangular, e.g., square cross-section, with preferred width and depth dimensions of between about 10 μm to about 500 μm, and about 0.5 μm to about 50 μm, respectively. Micro-channels may also be elliptical or round. Fluids flowing in the microchannels may exhibit microfluidic behavior such as low Reynolds number and low turbulence. The microchannel channel has an internal dimension (referred to as a particle-flow dimension), defined by height H, which determines the maximum particle size that can enter the microchannel channel.


Where the microchannel includes a deformable wall portion, the deformable wall portion typically defines the particle-flow dimension, which is indicated as height h. This dimension is adjustable, using pneumatic pressure, from a relaxed condition, which prevents the passage of particles of a preselected size, to an expanded position, which allows the passage of these particles.


A “channel segment” is a particular structural or functional portion of a microchannel device, optionally in combination with one or more ports.


A “microfluidic body” refers to a device having various stations, wells, or reservoirs connected by micron-scale microchannels in which fluids will exhibit microfluidic behavior in their flow through the channels.


As used herein, “fluid contact” means arranged so as to allow fluid to flow from one vessel, chamber, or conduit to another, as described herein and as understood in the art. Fluid contact is synonymous with “fluid communication.”


The terms “elastomer” and “elastomeric” should be given their standard meaning as used in the art. Allcock et al. (Contemporary Polymer Chemistry, 2nd Ed.) describes elastomers as polymers existing at a temperature between their glass transition temperature and liquefaction temperature. Elastomers generally deform under force and return to their original shape when the force is removed. The elasticity exhibited by elastomeric materials can be characterized by a Young's modulus. Elastomers for use with the microfluidic particle trapping device include but are not limited to polydimethylsiloxane (PDMS), polyisoprene, polybutadiene, polychloroprene, polyisobutylene, poly(styrene-butadiene-styrene), and members of the polyurethane and silicone families. Additional examples are provided in U.S. Pat. No. 7,144,616, which is incorporated herein by reference in its entirety for all purposes.


As used herein, “deformable” means readily changing shape or dimensions in response to stress or strain. Stress or strain includes fluid and pneumatic pressure. Upon the application of stress, deformable structures change shape from a relaxed condition to an expanded, compressed, bent, twisted, or distorted condition.


As used herein, “trapping” or “capturing” are used interchangeably to mean substantially immobilizing or confining between two elastomeric layers and/or between an elastic layer and an inelastic layer. A particle trapping region is synonymous with a particle capture region.


“Substantial fluid exchange” means replacement of fluid by ingress of a different fluid, as in washing particles immobilized in a column. Fluid exchange is substantial when at least 90%, and preferably at least 95% of fluid is replaced.


As used herein, a “port” is a point of ingress or egress for fluids and or gas. Fluids and gases may be provided to a port under pressure (including both positive and negative pressure), and may be delivered to a location within a microfluidic particle trapping device via microchannels.


As used herein, “pneumatic pressure” means pressure originating from air pressure, although air (or an inert or non-interfering gas) and/or fluid may contact the port of the device. Preferred pneumatic pressures are from about 0.1 pound per square inch (psi) to about 10 psi, from about 0.5 psi to about 7 psi, and from about 1 psi to about 5 psi. Exemplary pressures include, e.g., 1, 2, 3, 4, and 5 psi.


As used herein, “fluid pressure” means pressure exerted by a fluid, although the fluid pressure may be the result of pneumatic, hydraulic, gravitational, or capillary pressure. Preferred fluid pressures are from about 0.1 pound psi to about 10 psi, from about 0.5 psi to about 7 psi, and from about 1 psi to about 5 psi. Exemplary pressures include, e.g., 1, 2, 3, 4, and 5 psi.


The “substrate” is the base of the device, and may be transparent, at least under the trapping regions, to allow their visualization by microscopy or other optical methods. Alternatively, the substrate may include a light filtering or contrast-enhancing agent to assist in the assay. Examples of suitable substrates are glass (exemplified herein) and polycarbonate. Many other materials are suitable, depending on the application, and soft lithographic bonding on a substrate is known in the art (see, e.g., U.S. Pat. No. 7,144,616, which is incorporated herein by reference in its entirety for all purposes).


As used herein, the “height (h, h′. h′″, etc.)” of the microfluidic channel trapping/capturing region is the particle-flow dimension corresponding to the distance separating the inside surface of the deformable wall portion from the opposite wall of the microfluidic channel. This internal dimension determines the diameter of the particles that can be trapped by the device


As used herein, “height H” of a microfluidic channel is the particle-flow dimension. Microfluidic channels having deformable wall portions have a “height h”, which is the particle flow-dimension defined by the deformable wall portions. “H” and “h” are sometimes used to indicate the h has changed with respect to another drawing.


B. Particle Trapping Mechanisms

The device and method are best described with reference to the accompanying Figures. Common features are generally assigned the same numbers.



FIGS. 1A-C show a top (A) and side (B and C) views of simple embodiment of the microfluidic particle trapping device. A microfluidic body 86 has an inlet port 80 and outlet port 85 in fluid contact with a microfluidic channel. The microchannel has a particle trapping region 82 with a deformable wall portion 83, in fluid contact with secondary microchannel segments, e.g., 84, which are in contact with the ports 80 and 85. The secondary channel segments may be relatively nondeformable as suggested by the use of heavier lines.



FIG. 1D shows a top view of an embodiment of the microfluidic particle trapping device for particle analysis. The microfluidic body 116 is bonded to a substrate 118, such as a glass or plastic. The particle inlet port 102, solution inlet port 104, and solution outlet port 106, are in fluid contact with a microfluidic channel having a particle trapping region 112, via secondary microchannels 108 and 110. The particle inlet port and solution inlet port in combination with the associated microchannels, are generally referred to as inlet channel segments. The solution outlet port 106, in combination with the associated microchannels, is generally referred to as an outlet channel segment. The ports are generally adapted for receiving pneumatic pressures. As used herein, the particle inlet port 102 is upstream of the particle trapping region 112, while the solution inlet port 104, and solution outlet port 106 are downstream. Note that the arrangement of the various ports is not critical in some embodiments. The terms “upstream” and “downstream” are used to describe flow characteristics in different embodiments.



FIGS. 2A-2C show cross-sectional views (A-A′) of the microfluidic particle trapping device in different stages of operation. The deformable wall portion 207 of the particle trapping region 112 is preferably made of an elastomer, such as PDMS (polydimethylsiloxane), such that the deformable wall changes from a relaxed condition to an expanded position in response to fluid pressure (e.g., as provided by pneumatic pressure). As shown in FIG. 2A, an internal dimension (height “h”) is defined by the position of the deformable wall portion 207 of the particle trapping region 112. The secondary microchannels (i.e., 108 and 110) are designed such that their height (“H”) is larger than the particle diameter. Although the deformable wall portions are generally depicted as having thicker channel-wall sections than the adjacent microchannel, the deformable wall portions may have thicker or thinner walls than the adjacent microchannel.


In other embodiments, a deformable wall portions relaxed condition, at which particles of a selected size are prevented from entering the particle capture region, to a first expanded position at which particles of a selected size may enter the capture region, and from the.


As shown in FIG. 2B, when a first pneumatic pressure is applied to the inlet port 102, the fluid pressure in the microfluidic channel increases and h′ defined by the deformable wall portion 207 of the particle trapping region 112 becomes greater than the diameter of the particles 114, allowing the particles to move freely within the trapping region 112. When the inlet port 102 is pressurized to a second pneumatic pressure, as depicted in FIG. 2C, the fluid pressure in the microfluidic channel decreases, the deformable wall portion 207 defines a height of less than the particle diameter. Particles 114 present within the trapping region 112 are trapped (i.e., captured) by being sandwiched between the deformable wall of the microfluidic channel 207 and the bottom surface (substrate) 118 of the microfluidic device. Since the deformable wall is typically biased toward trapping the particles, the second pneumatic pressure may be zero (i.e., the same as the pressure external to the device), in which case, applying a second pneumatic pressure means allowing the deformable wall to return to its relaxed state or condition.


In other embodiments, the deformable wall portion is first deformed from a relaxed condition, at which particles of a selected size are prevented from entering the particle capture region, to a first expanded position, in which particles of a selected size may enter the capture region, and from the first expanded position to a second expanded position, in which the particles become trapped within said capture region. Pressure to drive the deformable wall portion from the first expanded position to a second expanded position may be provided via the ports or applied to the external surface of the microfluidic channels (see infra).


The trapped particles may then be exposed to (i.e., addressed with) a solution from port 104, e.g., by pressurizing the port with sufficient pressure to cause the solution to flow through the trapping region 112 to contact the particles 114, but insufficient to deform the deformable wall portion, allowing the particles to move or escape. The trapped particles may also be address with multiple solutions, for example, in a series or a particular sequence.


In preferred embodiments, addressing the trapped particles with a solution causes the particles to be displaced by less than about 10% of the size of the particles. For example, a trapped particle of about 10 μm diameter is displaced by only about 1 μm.



FIGS. 3A and 3B illustrate a further embodiment of the microfluidic particle trapping device 116 having additional features, which may be used alone or in combination. First, the embodiment has an additional port 202 in fluid contact with the inlet port 102. Following the release of pressure and the trapping of particles in the trapping region, the additional port 202 allows particles outside the trapping region 112 to be flushed from the microfluidic particle trapping device by means of fluid flow from additional port 202 to inlet port 102 or from inlet port 102 to additional port 202. Depending on the direction of flow, the additional port 202 is considered part of the inlet channel segment or outlet channel segment.


Second, the embodiment shown in FIGS. 3A and 3B has a first and second trapping region 204 and 210, respectively, with independent deformable walls portion 208 and 209, respectively, or sharing a common deformable wall portion that defines different particle-flow dimensions. According to this embodiment, the microfluidic channel has dimensions h″ and h′″, which are adjustable by pneumatic pressure for trapping particles having different diameters. The particle trapping device may have any number of longitudinally spaced trapping/capture regions, for example, 1, 2, 3, 4, 5, etc. In some embodiments, the particle-flow dimension decreases with each successive trapping segment, such that the particle-flow dimension of the trapping segment most proximal to the particle inlet 102 is greatest and that most distal to the particle inlet is least.


Third the embodiment shown in FIGS. 3A and 3B further incorporates a microfluidic mesh region 206 having a mesh size less than the diameter of the particles to prevent the particles leaving the trapping region 204 and 210 (i.e., flowing through the trapping region and out the solution inlet port 104 or outlet port 106. The microfluidic mesh region 206 is particularly useful when multiple solution inlet ports 104 are arrayed along a common solution-introduction channel 104. In such cases, the mesh region 206 prevents particles introduced to one particle inlet port from migrating through the adjacent trapping layer, and then exiting the device downstream of the trapping layer. The mesh region 206 is shown in contact with the substrate 118 but may be spaced apart so long as the particles do not escape. A trapping layer with a small particle flow dimension may also be used to prevent particles from leaving the trapping region.



FIGS. 4A and 4B show cross-sectional views of an embodiment of the microfluidic particle trapping device having a deformable wall portion with a cavity 211. At the first pneumatic pressure, with the deformable wall portion in the expanded condition, the internal dimension (h′) is greater than the diameter of the particles 114, allowing the particles from the particle inlet port 102 to flow freely under the deformable wall portion. At the second pneumatic pressure, with the deformable wall portion in the relaxed condition, the particles are trapped between the deformable wall portion 211 and the substrate/base 118.


The previous embodiments of the device are described with reference to applying a positive pressure to the microfluidic channel via the ports, thereby increasing the pressure inside the channel relative to the pressure outside the channel, and causing the deformable wall portion to change shape. In another embodiment, the pressure in the microfluidic channel is increased, relative to the pressure outside the chamber, by exposing the outside surface of the microfluidic chamber, adjacent to the deformable wall portion, to a negative pressure, i.e., a vacuum. This may be accomplished by applying localized vacuum to a suitably adapted embodiment of the microfluidic device, or by placing the microfluidic body in a vacuum chamber, while the ports remain exposed to atmospheric pressure. This embodiment is shown in FIGS. 5A and 5B.


The deformable wall portion 207, trapping portion 112, substrate 118, are essentially as described. The format of the particle inlet port 102 is different. Surfaces exposed to vacuum are inside the box. Outside the box is atmospheric pressure (or at least less vacuum pressure than inside the box). When vacuum is applied, the internal dimension (h′) is greater than the diameter of the particles 114. When vacuum is released, the particles 114 are trapped by the deformable wall portion 207.



FIG. 6 is a graph showing the relationship between the height (h) of the trapping region and the pneumatic pressure applied to the device. When a pneumatic pressure (x-axis) is applied, e.g., via the inlet port or solution port, the fluid pressure in the microfluidic channel changes and the deformable wall of the trapping region experiences height deformation (y-axis). Generally, the greater the positive pressure in the trapping region, the greater the height (h) of the trapping region. The critical pressure is the pressure at which the height of the trapping region is substantially equal to the diameter of the particle. When the applied pressure is greater than the critical pressure, the particles can move freely within or through the trapping region. When the applied pressure is less than the critical pressure, the particles within the trapping region are trapped. One skilled in the art will recognize that there are numerous ways to produce the small pressure differential required for deforming a deformable wall.


C. Yeast Cell Imaging Device


FIG. 7 is a schematic diagram of another embodiment of the microfluidic particle trapping device. The trapping regions are placed close to each other for the convenience of microscopic analysis. The device provides up to four solution-switching stations (e.g., solution inlet ports 104, A-D) for analyzing the trapped particles. FIG. 7 shows a more detailed view of the particle trapping regions 112. In this example, there are 16 particle trapping regions 112 inside the single field of view of a 10× objective. A particle inlet port 102, solution inlet port 104, and solution outlet port 106 are indicated.



FIG. 9 shows an image of an actual fabricated embodiment of the device for yeast cell imaging. The device is similar to that shown in the schematic in FIG. 7. This particular embodiment of the device is 24 mm in width and 60 mm in length, with microchannels of 30 μm in height, and two trapping regions having internal dimensions of 8 μm and 3 μm, respectively. In this example, there are 16 yeast cell trapping regions arrayed along a common flow channel.



FIG. 10A shows a detailed view of the imaging area indicated in FIG. 9. The imaging area includes the trapping regions with deformable wall portions. FIG. 10B shows an image of yeast trapped in the trap area indicated in FIG. 10A. Up to 4 trapping regions are visible under a single field of a 20× objective microscope lens. Yeast cells for use with this embodiment have an average size of 5 μm; therefore, the yeast cells are trapped only in the 3 μm trapping region. The device is capable of trapping yeast from up to 16 different particle preparations (for example, 16 yeast strains, each with a different genetic modification), and introducing up to 4 different reagents, e.g., for yeast gene expression study.


D. Microfluidic Bead-Based Immunoassay

In related embodiments, the microfluidic particle trapping body 116 is adapted for “lab-on-a-chip” diagnosis. FIG. 11 shows a schematic design of a microfluidic bead-based immunoassay chip embodiment of the device. The exemplary assay uses the “sandwich” immunoassay method. Different biomarkers (e.g., antibodies for different disease-associated antigens) can be immobilized on beads and introduced into the trapping regions 112, which are similar to those depicted in FIGS. 10A and 10B. A microfluidic mesh region 206, or an additional trapping layer having an insufficient height to allow the passage of the particles 204, may optionally be used to prevent the beads from one trapping region from crossing into other trapping regions.


After the beads are trapped (as shown in FIG. 12), a solution or suspension, such as a patient's serum, is introduced into the trapping regions 112 from an inlet port 104 at a pressure insufficient to raise the height of the trapping region, thereby exposing the trapped beads coated with different antibodies to the serum without releasing the beads from the trapping region. Matching antigens present in the serum bind to the antibody coated beads. After washing out the serum (e.g., with a saline solution, such as PBS), an antibody mixture with specificity to the desired antigens is introduced to label the bound antigens. A secondary antibody and fluorescent substrate is typically then introduced, and the calorimetric, fluorescent, radioactive, or other signal can be analyzed using standard detection methods, where the signal from each microchamber is correlated to a specific antigen, such as a biomarker.


A key feature of this immunoassay that distinguishes it from other chip-based diagnostic assays is that the trapping region acts like a “concentrator” by packing the beads into a single layer. In this manner, particles present in three-dimensional space (i.e., in a fluid volume) are concentrated into essentially two-dimensions, because the third dimension is approximately the same height as the trapped particles. Concentrating the particles greatly increased the signal-to-noise ratio compared to conventional assays.


E. Microfabrication Methods


FIGS. 13A-13K show an exemplary method for manufacturing a microfluidic particle trapping device. The various steps are labeled A-K. The process starts with a blank, 4″ test-grade silicon wafer (A). A negative photoresist (SU8 2002 Microchem) is spin coated at a final thickness of 3 μm and the first trapping region is patterned through standard photolithography (B). A second layer of negative photoresist (SU8 2005 Microchem) is spin coated at a final thickness of 8 μm and the second trapping region is patterned through standard photolithography (C). A third layer of negative photoresist (SU8 2025 Microchem) is spin coated at a final thickness of 30 μm and the rest of the microfluidic structures are patterned through standard photolithography (D). The mold is then coated with a 100 nm thick fluoropolymer using C4F8 plasma (1 torr, 300 W, 3 minutes, Surface Technology System) to create an extremely hydrophobic surface (contact angle ˜140° C.) to increase mold durability and prevent PDMS stiction (E).


The molding process starts with pouring 1.5 mL PDMS (Sylgard 184, Dow Corning, 10-parts monomer mixed with 1-part curing agent) on the 4″ fluoropolymer-coated silicon mold (F). The PDMS is degassed in a vacuum chamber (26″ Hg for 30 minutes to remove bubbles generated during the mixing). A 3 mm thick PMMA sheet is spin coated with a primer (Sylgard PrimeCoat, Dow Corning) and pressed onto the mold (G). The mold is placed in a 60° C. oven for 2 hours to allow the PDMS to cure. After removing the mold from the oven, the PMMA sheet is detached from the silicon mold (H). Because the surface of the PMMA sheet is modified by the primer, the cured PDMS adheres to the PMMA sheet and is detached from the silicon mold with the PMMA sheet. Fluidic reservoirs are cut by a CO2 laser writer (VersaLaser, 25W) (I). The laser writer is equipped with precise step motors; therefore, the reservoirs can be cut at specific locations with high accuracy. The mold replicate is then bonded to a #1 coverglass (J) after oxygen plasma treatment (200 mtorr, 10 W, 15 seconds, TechnicsLab) to render the PDMS surface hydroxyl group rich. The device is then primed with distilled deionized water and sealed with gas impermeable tape to avoid evaporation before use (K).


Exemplary embodiments of the device are shown in FIGS. 14A and 14B. The device may be connected to a manifold of a control box (or pressure regulator) for applying pneumatic pressure, such as the unit shown in FIG. 14. The device slides into the manifold, where a silicone gasket with openings aligns with the reservoirs of the device. The center (seal/release) knob is hand tightened so the silicone gasket and the device form a seal. An imaging window is cut from the bottom of the manifold to enable microscopy. The control box can be connected to a laboratory air pressure line, air compressor pump, or other suitable source of air pressure. The control box is equipped with a precision pressure regulator (0 to 5 psi) to control the flow rate and the amount of deformation of the trapping regions.


The above description and illustrations are provided only to exemplify the methods and the device for particle analysis. Addition aspects and embodiments will be apparent to the skilled artisan without departing from the scope of the invention.

Claims
  • 1. A microfluidic particle analysis device comprising: a microfluidics body having a bottom surface;a particle inlet port;a microfluidics channel in said body holding a fluid flow of a liquid containing one or more cell-sized particles, said fluid flow provided via the particle inlet port in communication with a first end of said microfluidics channel;a solution inlet port;a solution outlet port;a secondary microchannel in fluid communication with said solution inlet port, said solution outlet port and a second end of said microfluidics channel; andat least one trapping region in said microfluidics channel between said first end and said second end, said at least one trapping region comprising a deformable wall portion with a cavity therein, configured to have two operational heights when subjected to two different operational pressures, the two operational heights of the deformable wall portion, comprising: a first height configured to allow one or more cell-sized particles of interest to pass between the deformable wall portion and said bottom surface into said cavity via said fluid flow in said channel; anda second height configured to trap one or more cell-sized particles of a given size within said cavity of trapping region of said channel by reducing a dimension between the deformable wall portion and said bottom surface so that the cell-sized particles cannot exit the cavity;wherein, at the two operational heights, the cell-sized particles disposed in the trapping zone remain in fluid communication with the secondary microchannel.
  • 2. The device of claim 1, wherein the second height of said deformable wall portion comprises a relaxed condition, at which particles of a selected size are prevented from entering the trapping region, and said first height comprises an expanded position at which particles of said selected size may enter and flow through the trapping region.
  • 3. The device of claim 1, further comprising a microfluidic mesh in fluid contact with the microfluidic channel, wherein the mesh prevents the passage of particles from the microfluidic channel to a channel downstream of said trapping region.
  • 4. The device of claim 1, wherein the microfluidic channel has a plurality of longitudinally spaces trapping regions, each defined by a respective deformable wall portion and cavity, each trapping region configured to trap particles of a different size.
  • 5. The device of claim 1, wherein said two different operational pressures are provided by pneumatic pressure delivered to said port.
  • 6. The device of claim 1, wherein said two different operational pressures are provided by modifying a pressure at an outside surface of the deformable wall portion.
  • 7. The device of claim 1, wherein the deformable wall portion is formed of a deformable polymer selected from the group consisting of polydimethylsiloxane (PDMS), polyisoprene, polybutadiene, polychloroprene, polyisobutylene, poly(styrene-butadiene-styrene), polyurethane, and silicone.
  • 8. The device of claim 1, wherein the deformable wall portion comprises an extended portion on each opposite end of the cavity, and wherein an entirety of the deformable wall portion moves between the first height and the second height, such that a difference in height between the extended portions and the cavity remains constant.
  • 9. A method of analyzing cells comprising: flowing fluid comprising one or more cell-sized particles of interest in a microfluidics channel, the channel being part of a microfluidics body, the microfluidics body further comprising a particle inlet port in communication with a first end of said microfluidics channel;a solution inlet port;a solution outlet port;a secondary microchannel in fluid communication with said solution inlet port, said solution outlet port and a second end of said microfluidics channel; andat least one trapping region in said microfluidics channel between said first end and said second end, said at least one trapping region comprising a deformable wall portion configured to have two operational heights when subjected to two different operational pressures;applying a first operational pressure to the deformable wall portion to allow the one or more cell-sized particles of interest to pass into said trapping region via said fluid flow in said channel; andapplying a second operational pressure to the deformable wall portion to trap one or more cell-sized particles of a given size within said trapping region of said channel;wherein, at the two operational heights, the cell-sized particles disposed in the trapping zone remain in fluid communication with the secondary microchannel.
  • 10. The method of claim 9, wherein said two different operational pressures are provided by pneumatic pressure delivered to said port.
  • 11. The method of claim 9, wherein said two different operational pressured are provided by modifying a pressure at an outside surface of the deformable wall portion.
  • 12. The method of claim 9, wherein the deformable wall comprises a cavity, and wherein the cell-sized particles are trapped in the cavity when the deformable wall is at the second height.
  • 13. The method of claim 9, wherein the deformable wall portion comprises an extended portion on each opposite end of the cavity, and wherein an entirety of the deformable wall portion moves between the first height and the second height, such that a difference in height between the extended portions and the cavity remains constant.
  • 14. The device of claim 1, further comprising an additional port in fluid contact with the particle inlet port, disposed proximate the first end of the microfluidic channel.
Parent Case Info

This application is a continuation of U.S. patent application Ser. No. 15/163,398 filed May 24, 2016, (now U.S. Pat. No. 10,054,536 issued Aug. 1, 2018) which is a continuation of U.S. patent application Ser. No. 12/019,857 filed Jan. 25, 2008 (now U.S. Pat. No. 9,354,156 issued May 31, 2016), which claims priority to U.S. Provisional Patent Application No. 60/900,651 filed on Feb. 8, 2007, which is incorporated herein in its entirety by reference.

US Referenced Citations (203)
Number Name Date Kind
4055613 Kapral Oct 1977 A
4661455 Hubbard Apr 1987 A
4734373 Bartal Mar 1988 A
4748124 Vogler May 1988 A
5079168 Amiot Jan 1992 A
5153131 Wolf et al. Oct 1992 A
5310676 Johansson et al. May 1994 A
5330908 Spaulding Jul 1994 A
5376252 Ekstrom et al. Dec 1994 A
5416022 Amiot May 1995 A
5424209 Kearney Jun 1995 A
5437998 Schwarz et al. Aug 1995 A
5451524 Coble et al. Sep 1995 A
5462874 Wolf et al. Oct 1995 A
5565353 Klebe et al. Oct 1996 A
5589112 Spaulding Dec 1996 A
5593814 Matsuda et al. Jan 1997 A
5602028 Minchinton Feb 1997 A
5627070 Gruenberg May 1997 A
5637469 Wilding et al. Jun 1997 A
5641644 Klebe Jun 1997 A
5658797 Bader Aug 1997 A
5686301 Falkenberg et al. Nov 1997 A
5686304 Codner Nov 1997 A
5693537 Wilson et al. Dec 1997 A
5702941 Schwarz Dec 1997 A
5714384 Wilson et al. Feb 1998 A
5763261 Gruenberg Jun 1998 A
5763275 Nagels et al. Jun 1998 A
5763279 Schwarz et al. Jun 1998 A
5786215 Brown et al. Jul 1998 A
5793440 Nakasaka et al. Aug 1998 A
5801054 Kiel et al. Sep 1998 A
5866345 Wilding et al. Feb 1999 A
5882918 Goffe Mar 1999 A
5900361 Klebe May 1999 A
5912177 Turner et al. Jun 1999 A
5924583 Stevens et al. Jul 1999 A
5932315 Lum et al. Aug 1999 A
5942443 Parce et al. Aug 1999 A
6039897 Lochhead et al. Mar 2000 A
6048498 Kennedy Apr 2000 A
6096532 Armstrong et al. Aug 2000 A
6107085 Coughlin et al. Aug 2000 A
6153073 Dubrow et al. Nov 2000 A
6190913 Singh Feb 2001 B1
6197575 Griffith et al. Mar 2001 B1
6228635 Armstrong et al. May 2001 B1
6238908 Armstrong et al. May 2001 B1
6251343 Dubrow et al. Jun 2001 B1
6274337 Parce et al. Aug 2001 B1
6277642 Mentzen et al. Aug 2001 B1
6297046 Smith et al. Oct 2001 B1
6323022 Chang et al. Nov 2001 B1
6326211 Anderson et al. Dec 2001 B1
6403369 Wood Jun 2002 B1
6410309 Barbera-Guillem et al. Jun 2002 B1
6455310 Barbera-Guillem Sep 2002 B1
6465243 Okada et al. Oct 2002 B2
6468792 Bader Oct 2002 B1
6481648 Zimmerman Nov 2002 B1
6495104 Unno et al. Dec 2002 B1
6518035 Ashby et al. Feb 2003 B1
6534013 Kennedy Mar 2003 B1
6548263 Kapur et al. Apr 2003 B1
6551841 Wilding et al. Apr 2003 B1
6555365 Barbera-Guillem et al. Apr 2003 B2
6562616 Toner et al. May 2003 B1
6569675 Wall et al. May 2003 B2
6576458 Sarem et al. Jun 2003 B1
6585744 Griffith Jul 2003 B1
6585939 Dapprich Jul 2003 B1
6593136 Geiss Jul 2003 B1
6637463 Lei et al. Oct 2003 B1
6648015 Chow Nov 2003 B1
6653124 Freeman Nov 2003 B1
6673595 Barbera-Guillem Jan 2004 B2
6756019 Dubrow et al. Jun 2004 B1
6759245 Toner et al. Jul 2004 B1
6794184 Mohr et al. Sep 2004 B1
6811752 Barbera-Guillem Nov 2004 B2
6821772 Barbera-Guillem et al. Nov 2004 B2
6846668 Garman et al. Jan 2005 B1
6857449 Chow Feb 2005 B1
6908767 Bader Jun 2005 B2
6915679 Chien et al. Jul 2005 B2
6969166 Clark et al. Nov 2005 B2
7005292 Wilding et al. Feb 2006 B2
7018830 Wilding et al. Mar 2006 B2
7022518 Feye Apr 2006 B1
7067263 Parce et al. Jun 2006 B2
7141386 Dunfield et al. Nov 2006 B2
7155344 Parce et al. Dec 2006 B1
7160687 Kapur et al. Jan 2007 B1
7171983 Chien et al. Feb 2007 B2
7192769 Pykett et al. Mar 2007 B2
7223371 Hayenga et al. May 2007 B2
7343248 Parce et al. Mar 2008 B2
7745209 Martin et al. Jun 2010 B2
7919319 Jervis et al. Apr 2011 B2
8257964 Hung et al. Sep 2012 B2
8673625 Hung et al. Mar 2014 B2
8709790 Hung et al. Apr 2014 B2
9206384 Lee et al. Dec 2015 B2
9260688 Hung et al. Feb 2016 B2
9353342 Hung et al. May 2016 B2
9353343 Hung et al. May 2016 B2
9354156 Lee May 2016 B2
9371929 Hung et al. Jun 2016 B2
9376658 Hung et al. Jun 2016 B2
9388374 Hung et al. Jul 2016 B2
9428723 Lee et al. Aug 2016 B2
9637715 Hung et al. May 2017 B2
10054536 Lee et al. Aug 2018 B2
10138453 Hung et al. Nov 2018 B2
10174278 Hung et al. Jan 2019 B2
10179897 Hung et al. Jan 2019 B2
10190085 Lee et al. Jan 2019 B2
20020039785 Schroeder et al. Apr 2002 A1
20020108860 Staats Aug 2002 A1
20020110905 Barbera-Guillem et al. Aug 2002 A1
20020177221 Nishiguchi et al. Nov 2002 A1
20030003571 Kanegasaki Jan 2003 A1
20030008388 Barbera-Guillem et al. Jan 2003 A1
20030008389 Carll Jan 2003 A1
20030030184 Kim et al. Feb 2003 A1
20030040104 Barbera-Guillem Feb 2003 A1
20030124623 Yager et al. Jul 2003 A1
20030143727 Chang Jul 2003 A1
20030156992 Anderson et al. Aug 2003 A1
20030211012 Bergstrom et al. Nov 2003 A1
20030215941 Campbell et al. Nov 2003 A1
20040029266 Barbera-Guillem Feb 2004 A1
20040043481 Wilson Mar 2004 A1
20040072278 Chou et al. Apr 2004 A1
20040096960 Burd Mehta May 2004 A1
20040132175 Vetillard et al. Jul 2004 A1
20040202579 Larsson et al. Oct 2004 A1
20040229349 Daridon Nov 2004 A1
20040238484 Le Pioufle et al. Dec 2004 A1
20050009179 Gemmiti et al. Jan 2005 A1
20050019213 Kechagia et al. Jan 2005 A1
20050032208 Oh et al. Feb 2005 A1
20050101009 Wilson et al. May 2005 A1
20050106717 Wilson et al. May 2005 A1
20050072946 Studer et al. Jul 2005 A1
20050169962 Bhatia et al. Aug 2005 A1
20050214173 Facer et al. Sep 2005 A1
20050221373 Enzelberger Oct 2005 A1
20050260745 Domansky et al. Nov 2005 A1
20050266582 Modlin et al. Dec 2005 A1
20060003436 DiMilla et al. Jan 2006 A1
20060031955 West et al. Feb 2006 A1
20060112438 West et al. May 2006 A1
20060121606 Ito et al. Jun 2006 A1
20060136182 Vacanti et al. Jun 2006 A1
20060141617 Desai et al. Jun 2006 A1
20060154361 Wikswo et al. Jul 2006 A1
20060166354 Wikswo et al. Jul 2006 A1
20060199260 Zhang et al. Sep 2006 A1
20070026516 Martin et al. Feb 2007 A1
20070084706 Takayama et al. Apr 2007 A1
20070090166 Takayama et al. Apr 2007 A1
20070122314 Strand et al. May 2007 A1
20070128715 Vukasinovic et al. Jun 2007 A1
20070243523 Ionescu-Zanetti et al. Oct 2007 A1
20070264705 Dodgson Nov 2007 A1
20070275455 Hung et al. Nov 2007 A1
20080032380 Kleis et al. Feb 2008 A1
20080038713 Gao et al. Feb 2008 A1
20080085556 Graefing et al. Apr 2008 A1
20080176318 Wilson et al. Jul 2008 A1
20080194012 Lee et al. Aug 2008 A1
20080227176 Wilson Sep 2008 A1
20080233607 Yu et al. Sep 2008 A1
20080261295 Butler et al. Oct 2008 A1
20090023608 Hung et al. Jan 2009 A1
20090123961 Meyvantsson et al. May 2009 A1
20090148933 Battrell et al. Jun 2009 A1
20090203126 Hung et al. Aug 2009 A1
20090221073 Toner Sep 2009 A1
20100151571 Vukasinovic et al. Jun 2010 A1
20100196908 Opalsky et al. Aug 2010 A1
20100234674 Wheeler et al. Sep 2010 A1
20120003732 Hung et al. Jan 2012 A1
20120164036 Stern et al. Jun 2012 A1
20130059322 Hung et al. Mar 2013 A1
20130081757 Hung et al. Apr 2013 A1
20130090268 Hung et al. Apr 2013 A1
20130171679 Lee et al. Jul 2013 A1
20130171682 Hung et al. Jul 2013 A1
20140057311 Kamm et al. Feb 2014 A1
20140090735 Hung et al. Apr 2014 A1
20140099705 Hung et al. Apr 2014 A1
20140287489 Lee et al. Sep 2014 A1
20160075984 Hung et al. Mar 2016 A1
20160289623 Hung et al. Oct 2016 A1
20160312166 Lee et al. Oct 2016 A1
20160327470 Lee et al. Nov 2016 A1
20160333297 Hung et al. Nov 2016 A1
20160333298 Hung et al. Nov 2016 A1
20160340630 Hung et al. Nov 2016 A1
20170267961 Hung et al. Sep 2017 A1
Foreign Referenced Citations (21)
Number Date Country
201803927 Apr 2011 CN
19948087 May 2001 DE
0155237 Sep 1985 EP
0725134 Aug 1996 EP
0890636 Jan 1999 EP
1539263 Jan 1979 GB
9115570 Oct 1991 WO
0056870 Sep 2000 WO
0060352 Oct 2000 WO
0078932 Dec 2000 WO
0192462 Dec 2001 WO
03085080 Oct 2003 WO
03098218 Nov 2003 WO
2004059299 Jul 2004 WO
2004106484 Dec 2004 WO
2005035728 Apr 2005 WO
2007008606 Jan 2007 WO
2007008609 Jan 2007 WO
2009089189 Jul 2009 WO
2009102453 Aug 2009 WO
2012024646 Feb 2012 WO
Non-Patent Literature Citations (54)
Entry
Notice of allowance dated Jul. 20, 2018 in co-pending U.S. Appl. No. 15/163,368.
Notice of allowance dated Aug. 6, 2018 in co-pending U.S. Appl. No. 15/161,665.
Office action dated May 20, 2019 in co-pending U.S. Appl. No. 15/459,332.
Final rejection dated Jan. 23, 2019 in co-pending U.S. Appl. No. 15/175,749.
European communication dated Apr. 3, 2012 in co-pending European patent application No. 06786499.1.
International Search Report and Written Opinion dated Apr. 9, 2009 in PCT application No. PCT/US06/26364 (corresponding to U.S. Appl. No. 11/994,997).
International Search Report and Written Opinion dated Jul. 30, 2009 in co-pending PCT application No. PCT/US2009/030168.
European communication dated Oct. 21, 2013 in co-pending European patent application No. 09701350.2.
International Search Report dated May 14, 2013 in co-pending PCT application No. PCT/US2013/024999.
International Search Report dated Mar. 19, 2013 in co-pending PCT application No. PCT/US2012/067632.
International Preliminary Report on Patentability dated Jun. 12, 2014 in co-pending PCT application no. PCT/US2012/067632.
Eurpoean communication dated Jul. 28, 2015 in co-pending European patent application No. 12852539.1.
Japanese communication, with English translation, dated Nov. 17, 2015 in co-pending Japanese patent application No. 2015-503203.
Chinese communication, with English translation, dated Jun. 20, 2016 in co-pending Chinese patent application No. 201380018324.1
Engineering Aspects of Food Biotechnology, Chapter 5, CRC Press: Boca Raton, FL, 2004, copyright 2014, p. 127, “Meet the Stem Cells; Production of Cultured Meat from a Stem Cell Biology Perspective”, Brinkhof, et al., 3 pages.
Cellasic Corporation, ONIX Application Note, “Microincubator for long term live cell microscopy”, Feb. 3, 2012, pp. 1-4.
Optics Express, vol. 14, No. 13, Jun. 2006, pp. 6253-6256, “Fabrication of polymer microlens arrays using capillary forming with a soft mold of micro-holes array and UV-curable polymer”, Chang, et al.
Lab Chip, 2007, vol. 7, pp. 641-643, published by the Royal Society of Chemistry, “Rapid fabrication of microchannels using microscale plasma activated templating (uPLAT) generated water molds”, Chao, et al.
Lab on a Chip, 2007, vol. 7, pp. 763-769, “A hydrogel-based microfluidic device for the studies of directed cell migration”, Cheng, et al.
Lab Chip, 2005, vol. 5, No. 4, pp. 401-406, published by the Royal Society of Chemistry, “Human neural stem growth and differentiation in a gradient-generating microfluidic device”, Chung, et al.
Lab on a Chip, 2008, vol. 9, Iss.2 pp. 269-275, “Cell Migration into Scaffolds Under Co-culture Conditions in a Microfluidic Platform,” Chung et al.
J. Biochem., vol. 130, pp. 367-376, (2001), “A Method for Micrometer Resolution Patterning of Primary Culture Neurons for SPM Analysis”, Degenaar, et al.
Biotechnology and Bioengineering, vol. 89, No. 1, Jan. 5, 2005, pp. 1-8, “Continuous Perfusion Microfluidic Cell Culture Array for High-Throughput Cell-Based Assays”, Hung, et al.
Lab Chip, 2005, vol. 5, pp. 44-48, “A novel high aspect ratio microfluidic design to provide a stable and uniform microenvironment for cell growth in a high throughput mammalian cell culture array”, Hung, et al.
Lab Chip, 2008, vol. 8, No. 1, pp. 34-57, published by the Royal Society of Chemistry, “Biomolecular gradients in cell culture systems”, Keenan, et al.
Keenan et al., “A new method for studying gradient-induced neutrophil desensitization based on an open microfluidic chamber”, Lab Chip, 2010, vol. 10, pp. 116-122.
Lab on a Chip, 2009, vol. 9, p. 1797-1800, “Selective and tunable gradient device for cell culture and chemotaxis study”, Kim, et al.
Biotechnology and Bioengineering, vol. 97, No. 5, Aug. 1, 2007, pp. 1340-1346, “An Artificial Liver Sinusoid With a Microfluidic Endothelial-Like Barrier for Primary Hepatocyte Culture”, Lee, et al.
Lab Chip, 2009, vol. 9, No. 1, pp. 164-166, published by the Royal Society of Chemistry, “Dynamic cell culture: a microfluidic function generator for live cell microscopy”, Lee, et al.
Journal of the Association for Laboratory Automation (JALA), 2007, vol. 12, No. 6, pp. 363-367, “Microfluidic System for Automated Cell-Based Assays”, Lee, et al.
Lee et al., “Microfluidic Systems for Live Cell Imaging”, Methods in Cell Biology, 2011, vol. 102, pp. 77-103.
Lab Chip, 2003, vol. 3, pp. 318-323, published by the the Royal Society of Chemistry, “Fabrication of microfluidic mixers and artificial vasculatures using a high-brightness diode-pumped Nd: YAG laser direct write method”, Lim, et al.
Biomed Microdevices (2008), vol. 10, pp. 499-507, “Microfluidic switching system for analyzing chemotaxis responses of wortmannin-inhibited HL-60 cells”, Liu, et al.
Biomaterials, 2008, vol. 29, No. 22, pp. 3237-3244, “A gel-free 3D microfluidic cell culture system”, Ong, et al.
Lab on a Chip, 2007, vol. 7, pp. 1673-1680, “Gradient generation by an osmotic pump and the behavior of human mesenchymal stem cells under the fetal bovine serum concentration gradient”, Park, et al.
Angew. Chem. Int. Ed., 2004, vol. 43, pp. 1531-1536, “Minimal Functional Model of Hemostasis in a Biomimetic Microfluidic System”, Runyon, et al.
Biomedical Microdevices, 2003, vol. 5, No. 3, pp. 235-244, “Microfluidic Patterning of Cellular Biopolymer Matrices for Biomimetic 3-D Structures”, Tan, et al.
Office action dated Apr. 18, 2018 in co-pending U.S. Appl. No. 15/175,449.
Office action dated Feb. 20, 2018 in co-pending U.S. Appl. No. 15/163,398.
Ex Parte Quayle action mailed Apr. 24, 2018 in co-pending U.S. Appl. No. 15/163,398.
Notice of allowance dated Jun. 11, 2018 in co-pending U.S. Appl. No. 15/163,398.
Office action dated Apr. 11, 2018 in co-pending U.S. Appl. No. 15/163,368.
Office action dated Feb. 23, 2017 in co-pending U.S. Appl. No. 15/175,749.
Office action dated Nov. 1, 2017 in co-pending U.S. Appl. No. 15/175,749.
Final rejection dated Mar. 27, 2018 in co-pending U.S. Appl. No. 15/175,749.
Office action dated Jul. 10, 2018 in co-pending U.S. Appl. 15/175,749.
Office action dated Mar. 21, 2018 in co-pending U.S. Appl. No. 15/163,818.
Ex Parte Quayle action mailed May 21, 2018 in co-pending U.S. Appl. No. 15/163,818.
Notice of allowance dated Jul. 5, 2018 in co-pending U.S. Appl. No. 15/163,818.
Office action dated Jul. 6, 2017 in co-pending U.S. Appl. No. 15/161,665.
Notice of allowance dated Feb. 2, 2018 in co-pending U.S. Appl. No. 15/161,665.
Notice of allowance dated May 31, 2018 in co-pending U.S. Appl. No. 15/161,665.
Notice of allowance dated Aug. 27, 2019 in co-pending U.S. Appl. No. 15/459,332.
Notice of allowance dated Sep. 12, 2018 in co-pending U.S. Appl. No. 15/175,449.
Related Publications (1)
Number Date Country
20180275043 A1 Sep 2018 US
Provisional Applications (1)
Number Date Country
60900651 Feb 2007 US
Continuations (2)
Number Date Country
Parent 15163398 May 2016 US
Child 15958480 US
Parent 12019857 Jan 2008 US
Child 15163398 US